These findings support the critical role of hepatic CB1R in regulating these metabolic parameters, and further suggest that targeting hepatic CB1R can be considered a valid therapeutic approach for treating NAFLD and T2D. The gene discussed is CNR1; the disease is metabolic dysfunction-associated steatotic liver disease.